US Congress Senate Bill 1052 (Prior Session Legislation)

---

Spectrum: Bipartisan Bill
Status: Engrossed on August 4 2017 - 50% progression, died in committee
Action: 2017-08-11 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Engrossed) [PDF]

BENEFIT Act of 2017 Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2017 (Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to consider patient-focused drug development data, such as patient preferences, patient-reported outcomes, and patient experiences, as part of the risk-benefit assessment of new drugs. Following approval of a drug, the FDA must include a description of how this information was considered in its statement of patient experience.

BENEFIT Act of 2017 Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2017

Sen. Roger Wicker [R-MS]

Sen. Amy Klobuchar [D-MN]

Date	Chamber	Action
2017-08-11	House	Referred to the Subcommittee on Health.
2017-08-04	House	Referred to the House Committee on Energy and Commerce.
2017-08-04	House	Received in the House.
2017-08-03	Senate	Message on Senate action sent to the House.
2017-08-03	Senate	Passed Senate without amendment by Unanimous Consent. (text: CR S4788)
2017-08-03	Senate	Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S4787-4788)
2017-05-04	Senate	Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Type	Source
Summary	https://www.congress.gov/bill/115th-congress/senate-bill/1052/all-info
Text	https://www.congress.gov/115/bills/s1052/BILLS-115s1052is.pdf
Text	https://www.congress.gov/115/bills/s1052/BILLS-115s1052es.pdf